PubRank

Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC) (BRADYVASC)

Clinical Trial ID NCT02584439

PubWeight™ 0.00‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02584439

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006 17.53
2 Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006 10.05
3 Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med 2014 5.41
4 Is pulse pressure useful in predicting risk for coronary heart Disease? The Framingham heart study. Circulation 1999 5.04
5 Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008 5.03
6 Heart rate: an important confounder of pulse wave velocity assessment. Hypertension 2002 3.55
7 Influence of heart rate on mortality in a French population: role of age, gender, and blood pressure. Hypertension 1999 1.71
8 Comparative effects of ivabradine, a selective heart rate-lowering agent, and propranolol on systemic and cardiac haemodynamics at rest and during exercise. Br J Clin Pharmacol 2006 1.47
9 Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. Br J Pharmacol 2008 1.17
10 Heart rate-associated mechanical stress impairs carotid but not cerebral artery compliance in dyslipidemic atherosclerotic mice. Am J Physiol Heart Circ Physiol 2011 0.92
11 Brachial pressure-independent reduction in carotid stiffness after long-term angiotensin-converting enzyme inhibition in diabetic hypertensives. Hypertension 2006 0.92
12 Selective heart rate reduction with ivabradine unloads the left ventricle in heart failure patients. J Am Coll Cardiol 2013 0.87
13 Epoxyeicosatrienoic acids contribute with altered nitric oxide and endothelin-1 pathways to conduit artery endothelial dysfunction in essential hypertension. Circulation 2012 0.86
14 Hypertrophic remodeling and increased arterial stiffness in patients with intracranial aneurysms. Atherosclerosis 2010 0.81
15 Destiffening effect of valsartan and atenolol: influence of heart rate and blood pressure. J Hypertens 2014 0.79
16 Impaired role of epoxyeicosatrienoic acids in the regulation of basal conduit artery diameter during essential hypertension. Hypertension 2012 0.78
Next 100